Despite persistent macroeconomic headwinds — elevated interest rates, tightening regulatory scrutiny, and geopolitical fragmentation — the mergers and acquisitions landscape remains demonstrably active. A cluster of recent transactions, collectively exceeding $15 billion in disclosed deal value, confirms that strategic buyers and private equity sponsors have not stepped back from the market. They have simply become more deliberate. For CFOs, General Counsel, and M&A Directors navigating this environment, understanding what is driving deal momentum — and where friction points are emerging — is essential to positioning effectively for the next 12 to 18 months.

Large-Cap Transactions Are Setting the Tone for Mid-Market Activity

The most instructive signal from recent deal flow is the breadth of sectors involved. Amphenol’s completed $10.5 billion acquisition of CommScope’s Connectivity and Cable Solutions unit represents one of the largest technology-infrastructure consolidations of the year, reinforcing the thesis that connectivity and data infrastructure assets command premium valuations. Similarly, HNI Corporation’s $2.2 billion agreement to acquire Steelcase reflects a broader industrial consolidation trend, where scale economics and supply chain rationalisation are driving portfolio reshaping at the top of the market.

In healthcare, Alcon’s planned $1.5 billion purchase of STAAR Surgical underscores continued appetite for precision medical technology, a segment where regulatory barriers to entry create durable competitive moats and justify strategic premiums. Zebra Technologies’ move to acquire Elo Touch Solutions for $1.3 billion further illustrates how technology-enabled consolidation is blurring the lines between industrial and software-driven business models.

These large-cap transactions matter beyond their individual scale. They compress competitive dynamics in their respective sectors, accelerate mid-market consolidation as second-tier players respond, and recalibrate valuation benchmarks that buyers and sellers reference in due diligence processes across deal sizes.

Cross-Border Complexity Is Increasing — But So Is Strategic Appetite

Cross-border deal activity continues to be a defining feature of the current M&A cycle. European and U.S.-linked transactions in healthcare and technology are demonstrating that global buyers remain willing to absorb the additional complexity of international acquisitions — including multi-jurisdictional regulatory review, currency exposure, and integration across different legal and labour frameworks.

From a European perspective, this presents both opportunity and risk. The EU’s Foreign Subsidies Regulation (FSR), which entered into full force in October 2023, has added a new layer of mandatory notification for transactions involving companies that have received substantial foreign subsidies — a consideration that is now firmly embedded in pre-signing diligence for cross-border deals above relevant thresholds. Alongside existing merger control regimes under the EU Merger Regulation, acquirers must now account for longer regulatory timelines and the possibility of remedies or conditions that were not standard practice two years ago.

Sponsor-led activity adds further nuance. Take-private transactions — such as SERB Pharmaceutical’s move on Y-mAbs — reflect private equity’s continued conviction in healthcare assets, even as higher financing costs have compressed leverage multiples and reduced the pool of viable targets at certain price points. The strategic rationale for these deals increasingly rests on operational value creation rather than financial engineering alone.

Implications for Decision-Makers: Diligence, Integration, and Regulatory Readiness

For boards and executive teams evaluating transactions in this environment, several priorities deserve immediate attention:

  • Regulatory mapping must begin earlier. Whether a transaction triggers EU merger control, FSR notification, or sector-specific review (particularly in healthcare and critical infrastructure), the regulatory timeline now shapes deal structuring decisions — not just closing conditions. Engaging regulatory counsel at term sheet stage is no longer optional.
  • Post-merger integration planning is a valuation issue. Acquirers that can demonstrate a credible, detailed integration roadmap — covering systems, talent, customer relationships, and synergy capture — are consistently achieving better outcomes in competitive processes. Boards should expect management to present integration risk alongside financial projections.
  • Customer concentration and technology dependency require granular diligence. In both industrial technology and healthcare deals, revenue concentration in a small number of customers or reliance on proprietary technology platforms has become a primary risk factor that sophisticated buyers price into their offers.
  • Financing structures are evolving. With traditional leveraged finance more constrained, acquirers are increasingly combining equity, vendor financing, and structured instruments. Corporate finance teams should model multiple capital structure scenarios before entering competitive bid processes.

Key Takeaway

The M&A market in 2024 is not defined by volume alone — it is defined by selectivity, preparation, and execution discipline. The deals getting done are those where strategic logic is clear, regulatory risk is managed proactively, and post-merger integration is treated as a value driver rather than an afterthought. For mid-market companies and their advisors, the lesson from large-cap deal activity is straightforward: the bar for diligence and integration readiness has risen, and the buyers who meet that bar are the ones closing transactions on favourable terms.